Yahoo Finance Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update
Amy Mahery
Early launch data for VTAMA® (tapinarof) with approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch shows strong demand for first topical novel chemical entity for plaque psoriasis in 25 years
The Journal of the American Academy of Dermatology (JAAD) published the Phase 3 long-term extension study highlighting the unique mechanism for the remittive effect of VTAMA showing mean duration off-therapy for patients achieving PGA=0 was 130 days
Dermavant’s Japanese partner reported positive Phase 3 data for tapinarof for the treatment of atopic dermatitis (AD), including statistically significant results on the IGA and EASI scores, and plans to submit for approval in Japan
Enrollment in Priovant’s potentially registrational trial for brepocitinib in systemic lupus erythematosus (SLE) is expected to complete in August 2022, and topline data is on track to be announced in the second half of calendar year 2023
Amy Mahery has joined Roivant as Chief Commercial Officer from EMD Serono
On September 28, Roivant will host an investor day, providing updates on the ongoing VTAMA launch in psoriasis, clinical development at the Vants and continued progress from Roivant Discovery
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the first quarter ended June 30, 2022 and provided an update on the Company’s operations.
Roivant’s Chief Executive Officer, Matt Gline, noted: “I’m excited by the strong early signals we’re seeing from the ongoing VTAMA launch in psoriasis, including approximately 14,000 prescriptions in the first eleven weeks. The recent positive topline results from Torii Pharmaceutical and Japan Tobacco’s study of tapinarof in atopic dermatitis underscore our conviction in VTAMA’s potential in AD as our own Phase 3 trials progress. We are also pleased with recent execution across the rest of our pipeline, including the continued progress in our pivotal trials at Immunovant and Priovant. We are proud to advance the development of these important medicines for patients.”
Roivant also announced today that Amy Mahery will be joining the company as Chief Commercial Officer and will serve as a member of the leadership team. Amy has more than twenty years of industry experience and has been involved in the commercialization and launch of therapies across oncology, neurology and immunology. Most recently, she was the Senior Vice President and Head of the Global Business Franchise, Neurology and Immunology (N&I) at EMD Serono, where she led commercial strategy for the N&I portfolio from clinical development to launch and late lifecycle.
On September 28, Roivant will host an investor day, at which the Company will provide updates on the ongoing VTAMA launch in psoriasis, clinical development at the Vants and continued progress in drug discovery. The webcast for this virtual event will begin at 11 a.m. EDT, and participants can register to attend at https://hopin.com/events/roivantinvestorday2022/registration.
Recent Developments
Dermavant: Since its launch in late May, VTAMA has had approximately 14,000 prescriptions written by more than 3,000 unique prescribers based on the latest available IQVIA data through August 5 for prescriptions and July 29 for prescribers. VTAMA became the most prescribed branded topical for the treatment of psoriasis in the U.S. within eight weeks of launch. In July, Torii Pharmaceutical and Japan Tobacco announced positive topline results from their Phase 3 study of tapinarof in atopic dermatitis. In this trial, tapinarof showed statistical superiority to vehicle on the primary endpoint of efficacy, IGA response at week 8. In addition, tapinarof showed statistical superiority to vehicle for EASI achievement rate at week 8, a key secondary endpoint of efficacy. There were no new observed safety or tolerability findings reported.
Priovant: Priovant expects to complete enrollment for its ongoing potentially registrational global trial evaluating oral brepocitinib for the treatment of SLE in August 2022. Oral brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1 licensed from Pfizer that has been evaluated in 14 completed Phase 1 and Phase 2 trials, including 5 placebo-controlled Phase 2 trials in psoriatic arthritis, plaque psoriasis, ulcerative colitis, alopecia areata and hidradenitis suppurativa that generated statistically significant and clinically meaningful efficacy results. Priovant is also developing oral brepocitinib for the treatment of dermatomyositis, for which it recently initiated a single registrational Phase 3 trial.
Major Upcoming Milestones
Dermavant: Dermavant expects to provide updates on the commercial launch of VTAMA for psoriasis on a periodic basis and to report topline data from the Phase 3 trials of VTAMA for the treatment of atopic dermatitis in the first half of calendar year 2023.
Priovant: Priovant plans to announce topline results from the potentially registrational trial evaluating brepocitinib for the treatment of patients with SLE in the second half of calendar year 2023.
Immunovant: Immunovant plans to initiate two pivotal trials to evaluate batoclimab for the treatment of thyroid eye disease in the second half of calendar year 2022, with topline results expected in the first half of calendar year 2025. Immunovant plans to announce two new indications for batoclimab and the third indication (in addition to MG and TED) it will initiate as a pivotal trial in calendar year 2022 on an investor call scheduled for September 7, 2022.
Hemavant: Hemavant plans to announce data from the ongoing open-label Phase 1/2 trial evaluating RVT-2001 for the treatment of transfusion-dependent anemia in lower-risk MDS patients in the second half of calendar year 2023.
Kinevant: Kinevant plans to report topline data from the ongoing Phase 2 trial of namilumab for the treatment of sarcoidosis in the first half of calendar year 2024.
First Quarter Ended June 30, 2022 Financial Summary
Cash Position
As of June 30, 2022, we had cash, cash equivalents and restricted cash of approximately $2.0 billion.
Research and Development Expenses
Research and development (R&D) expenses were $135.8 million for the three months ended June 30, 2022 compared to $78.5 million for the three months ended June 30, 2021. The quarter-over-quarter increase was primarily due to increases in program-specific costs and personnel-related expenses, reflecting the progression of our programs and drug discovery. Additionally, share-based compensation expense increased largely as a result of the ongoing vesting of certain equity instruments for which the liquidity event vesting condition was met upon the closing of the business combination with MAAC in September 2021. We did not recognize share-based compensation expense related to these equity instruments during the three months ended June 30, 2021 as the liquidity event requirement had not been met and was not deemed probable of being met. Non-GAAP R&D expenses were $122.5 million for the three months ended June 30, 2022 compared to $76.2 million for the three months ended June 30, 2021.
Selling, General and Administrative Expenses
Selling, general and administrative (SG&A) expenses were $149.1 million for the three months ended June 30, 2022 compared to $82.8 million for the three months ended June 30, 2021. The quarter-over-quarter increase was primarily due to increases in share-based compensation expense largely as a result of the ongoing vesting of certain equity instruments for which the liquidity event vesting condition was met upon the closing of the business combination with MAAC in September 2021. We did not recognize share-based compensation expense related to these equity instruments during the three months ended June 30, 2021 as the liquidity event requirement had not been met and was not deemed probable of being met. Additionally, SG&A expenses for Dermavant have increased as a result of the commercial launch of VTAMA in May 2022. Non-GAAP SG&A expenses were $87.7 million for the three months ended June 30, 2022 compared to $64.4 million for the three months ended June 30, 2021.
Net Loss
Net loss was $353.8 million for the three months ended June 30, 2022 compared to $101.1 million for the three months ended June 30, 2021. On a per common share basis, net loss was $0.48 for the three months ended June 30, 2022 and $0.13 for the three months ended June 30, 2021. Non-GAAP net loss was $210.7 million for the three months ended June 30, 2022 compared to $133.4 million for the three months ended June 30, 2021.
ROIVANT SCIENCES LTD.
Selected Balance Sheet Data
(unaudited, in thousands)
| June 30, 2022 |
| March 31, 2022 | ||
|
|
|
| ||
Cash, cash equivalents and restricted cash | $ | 1,956,469 |
| $ | 2,074,034 |
Total assets |
| 2,600,398 |
|
| 2,585,129 |
Total liabilities |
| 822,516 |
|
| 523,695 |
Total shareholders’ equity |
| 1,755,391 |
|
| 2,038,943 |
Total liabilities, redeemable noncontrolling interest and shareholders’ equity |
| 2,600,398 |
|
| 2,585,129 |
ROIVANT SCIENCES LTD.
Condensed Consolidated Statements of Operations
(unaudited, in thousands, except share and per share amounts)
| Three Months Ended June 30, | ||||||
|
| 2022 |
|
|
| 2021 |
|
|
|
|
| ||||
Revenue, net | $ | 4,319 |
|
| $ | 7,735 |
|
Operating expenses: |
|
|
| ||||
Cost of revenues |
| 1,726 |
|
|
| 742 |
|
Research and development (includes $12,243 and $1,615 of share-based compensation expense for the three months ended June 30, 2022 and 2021, respectively) |
| 135,830 |
|
|
| 78,515 |
|
Acquired in-process research and development |
| — |
|
|
| 111 |
|
Selling, general and administrative (includes $60,551 and $17,654 of share-based compensation expense for the three months ended June 30, 2022 and 2021, respectively) |
| 149,072 |
|
|
| 82,754 |
|
Total operating expenses |
| 286,628 |
|
|
| 162,122 |
|
|
|
|
| ||||
Loss from operations |
| (282,309 | ) |
|
| (154,387 | ) |
|
|
|
| ||||
Change in fair value of investments |
| 24,547 |
|
|
| 8,619 |
|
Change in fair value of debt and liability instruments |
| 41,213 |
|
|
| 4,585 |
|
Gain on termination of Sumitomo Options |
| — |
|
|
| (66,472 | ) |
Other expense (income), net |
| 1,716 |
|
|
| (134 | ) |
Loss before income taxes |
| (349,785 | ) |
|
| (100,985 | ) |
Income tax expense |
| 3,999 |
|
|
| 93 |
|
Net loss |
| (353,784 | ) |
|
| (101,078 | ) |
Net loss attributable to noncontrolling interests |
| (21,975 | ) |
|
| (18,895 | ) |
Net loss attributable to Roivant Sciences Ltd. | $ | (331,809 | ) |
| $ | (82,183 | ) |
Net loss per common share—basic and diluted | $ | (0.48 | ) |
| $ | (0.13 | ) |
Weighted average shares outstanding—basic and diluted |
| 695,878,859 |
|
|
| 649,856,203 |
|
ROIVANT SCIENCES LTD.
Reconciliation of GAAP to Non-GAAP Financial Measures
(unaudited, in thousands)
|
|
| Three Months Ended June 30, | ||||||
| Note |
|
| 2022 |
|
|
| 2021 |
|
|
|
|
|
|
| ||||
Net loss |
|
| $ | (353,784 | ) |
| $ | (101,078 | ) |
Adjustments: |
|
|
|
|
| ||||
Cost of revenues |
|
|
|
|
| ||||
Amortization of intangible assets | (1) |
|
| 742 |
|
|
| — |
|
Research and development: |
|
|
|
|
| ||||
Share-based compensation | (2) |
|
| 12,243 |
|
|
| 1,615 |
|
Depreciation and amortization | (3) |
|
| 1,070 |
|
|
| 743 |
|
General and administrative: |
|
|
|
|
| ||||
Share-based compensation | (2) |
|
| 60,551 |
|
|
| 17,654 |
|
Depreciation and amortization | (3) |
|
| 866 |
|
|
| 744 |
|
Other: |
|
|
|
|
| ||||
Change in fair value of investments | (4) |
|
| 24,547 |
|
|
| 8,619 |
|
Change in fair value of debt and liability instruments | (5) |
|
| 41,213 |
|
|
| 4,585 |
|
Gain on termination of Sumitomo Options | (6) |
|
| — |
|
|
| (66,472 | ) |
Estimated income tax impact from adjustments | (7) |
|
| 1,873 |
|
|
| 216 |
|
|
|
|
|
|
| ||||
Adjusted net loss (Non-GAAP) |
|
| $ | (210,679 | ) |
| $ | (133,374 | ) |
|
|
| Three Months Ended June 30, | ||||
| Note |
|
| 2022 |
|
| 2021 |
|
|
|
|
|
| ||
Research and development expenses |
|
| $ | 135,830 |
| $ | 78,515 |
Adjustments: |
|
|
|
|
| ||
Share-based compensation | (2) |
|
| 12,243 |
|
| 1,615 |
Depreciation and amortization | (3) |
|
| 1,070 |
|
| 743 |
|
|
|
|
|
| ||
Adjusted research and development expenses (Non-GAAP) |
|
| $ | 122,517 |
| $ | 76,157 |
|
|
| Three Months Ended June 30, | ||||
| Note |
|
| 2022 |
|
| 2021 |
|
|
|
|
|
| ||
Selling, general and administrative expenses |
|
| $ | 149,072 |
| $ | 82,754 |
Adjustments: |
|
|
|
|
| ||
Share-based compensation | (2) |
|
| 60,551 |
|
| 17,654 |
Depreciation and amortization | (3) |
|
| 866 |
|
| 744 |
|
|
|
|
|
| ||
Adjusted selling, general and administrative expenses (Non-GAAP) |
|
| $ | 87,655 |
| $ | 64,356 |
Notes to non-GAAP financial measures:
(1) Represents non-cash amortization of intangible assets associated with milestone payments made in connection with regulatory approvals.
(2) Represents non-cash share-based compensation expense.
(3) Represents non-cash depreciation and amortization expense, other than amortization of intangible assets associated with milestone payments made in connection with regulatory approvals.
(4) Represents the unrealized loss (gain) on equity investments in unconsolidated entities that are accounted for at fair value with changes in value reported in earnings.
(5) Represents the change in fair value of debt and liability instruments, which is non-cash and primarily includes the unrealized loss (gain) relating to the measurement and recognition of fair value on a recurring basis of certain liabilities.
(6) Represents the one-time gain on termination of the options held by Sumitomo Pharma Co., Ltd. to purchase Roivant’s ownership interest in certain Vants (the “Sumitomo Options”).
(7) Represents the estimated tax effect of the adjustments.
Beginning in the fourth quarter of the fiscal year ended March 31, 2022, the Company no longer excludes from its non-GAAP financial measures acquired IPR&D expenses, which include consideration for the purchase of IPR&D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. Previously, these items were excluded from the Company’s non-GAAP financial measures. In conjunction with this change, acquired IPR&D expenses are now reported as a separate line item in its consolidated statements of operations. Prior period amounts have been revised to conform to the current presentation.
There was no acquired IPR&D expense for the three months ended June 30, 2022. For the three months ended June 30, 2021, acquired IPR&D expense was $0.1 million.
Investor Conference Call Information
Roivant will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 15, 2022 to report its financial results for the fiscal quarter ended June 30, 2022 and provide a corporate update.
To access the conference call by phone, please register online using this registration link. A webcast of the call will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant Sciences
Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" – nimble and focused biopharmaceutical and health technology companies. For more information, please visit www.roivant.com.
Roivant Sciences Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our products and product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our products and product candidates and any pending or potential litigation, including but not limited to our expectations regarding the outcome of any such litigation and costs and expenses associated with such litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. With the exception of VTAMA, which was approved by FDA for the treatment of plaque psoriasis in adults in May 2022, all products and product candidates referenced in this press release are investigational and subject to health authority approval.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors
Roivant Investor Relations
ir@roivant.com
Media
Paul Davis
Roivant Sciences
paul.davis@roivant.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0924bb93-afbb-4372-869b-3e190a5ae350
